ClinicalTrials.gg
CompletedNCT06348589Updated Nov 14, 2024

Orthostatic Hypotension and Blood Pressure Variability in Persons Undergoing Hemodialysis

An observational study in Chronic Kidney Disease Requiring Chronic Dialysis, sponsored by Vrinnevi Hospital. Completed at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2024-11-14.

Sponsored by Vrinnevi Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
25
Sex
All
01

Study summary

High blood pressure is a risk factor for end-stage renal disease and is common in patients undergoing maintenance hemodialysis. Intradialytic hypotension is associated with an adverse prognosis. More knowledge is needed to identify patients at high risk for intradialytic hypotension and dialysis-associated hypotensive episodes. The aim of this observational single-center pilot study is to evaluate whether point-of-care ultrasound measurements may predict intradialytic hypotension and orthostatic blood pressure falls, in patients with chronic kidney disease who undergo maintenance hemodialysis.

Read the detailed description

Background: Hypertension is an independent risk factor for development of end-stage renal disease and is the leading risk factor for cardiorenal death. It is estimated that more than 80% of patients with end-stage renal disease who undergo maintenance hemodialysis have hypertension. Intensified blood pressure control has been associated with reduced risk of death in patients with hypertension and chronic kidney disease but may increase the risk for intra-dialytic blood pressure falls in patients who undergo hemodialysis. Hemodialysis-associated hypotension has been associated with increased risks for cardiovascular disease and mortality.

Aim: The aim of this observational pilot study is to evaluate whether point-of-care ultrasound measurements may predict intradialytic hypotension and orthostatic blood pressure falls, in patients with chronic kidney disease who undergo maintenance hemodialysis.

Ethics: The study has been approved by the Swedish Ethical Review Authority (2023-05959-01).

Study participants: All patients (n=70) with chronic kidney disease who undergo maintenance hemodialysis at Vrinnevi Hospital in Norrköping, Sweden, will be invited to voluntarily participate in the study. Information about the study will be given orally and in written form. Those who opt to participate will be asked to sign a written informed consent.

Background data collection: For descriptive purposes, information will be collected regarding current and prior medical diagnoses, current medical treatment, anthropometric data, and self-perceived quality of lite (using the validated questionnaire KDQOL-SF). Blood samples will be tested for routine hematological variables, as well as for sodium, potassium, calcium, creatinine, urea and HbA1c.

Ultra-sound measurements: Before initiation of dialysis, point-of-care ultrasound measurements will be performed with the patient resting in a supine position at a 30 degrees angle, using a Sonosite SII ultrasound machine with a curvilinear probe. Measurements of the diameter of the inferior vena cava will be performed at a level approximately 2 cm from the right atrium, and breathing variability of its diameter will be assessed.

Blood pressure measurements: Systolic and diastolic blood pressure measurements will be performed after the patient has been resting for 5 minutes in the supine position, with a cuff size that is appropriate for each patient, with the arm resting at heart level, in the arm where the patient does not have a dialysis fistula, using an automated blood pressure measurement device (Fresenius 6008 CARE System) which is connected to the dialysis equipment. Two measurements (with one minute apart) will be performed 30 minutes before the dialysis session begins, three measurements will be performed after half of the planned dialysis session, and two measurements will be performed 15 minutes after the dialysis session has ended. An orthostatic test, which includes systolic and diastolic blood pressure measurements taken immediately after standing up and 1 and 3 minutes after standing up, will also be performed 30 minutes before the dialysis session begins and 15 minutes after the dialysis session has ended.

Statistics: Background information (demographics, anthropometrics, medical history, medication, biochemical evaluation) will be presented for the entire study population as means with standard deviations, medians with inter-quartile ranges, or as counts with percentages, as appropriate. These variables will also be presented in patients with and without intradialytic blood pressure falls (defined as an intradialytic reduction of systolic blood pressure ≥ 20 mmHg or of diastolic blood pressure ≥10 mmHg), and in patients with and without orthostatic blood pressure falls (defined as an orthostatic reduction of systolic blood pressure ≥ 20 mmHg or of diastolic blood pressure ≥10 mmHg), respectively. Between-group differences will be tested for statistical significance using Student´s t-test, Mann-Whitney U-test, Chi-square test or Fisher´s exact test, as appropriate.

Temporal changes in supine systolic and diastolic blood pressures (assessed prior to dialysis, during dialysis and after dialysis) will be visualized with regression slopes, and mixed models will be used to assess their associations with ultrasound measurements of the inferior vena cava. Associations between ultrasound measurements of the inferior vena cava and the blood pressure changes during the orthostatic blood pressure tests will be visualized with scatter plots and tested for statistical significance with correlation analysis.

The predictive ability of ultrasound measurements of the inferior vena cava and the occurrence of intra-dialytic blood pressure falls and of orthostatic blood pressure falls, respectively, will be assessed with logistic regression.

02

Conditions studied

  • Chronic Kidney Disease Requiring Chronic Dialysis
03

In context

Lead sponsor

Vrinnevi Hospital is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients (n=70) with chronic kidney disease who undergo maintenance hemodialysis at Vrinnevi Hospital in Norrköping, Sweden, will be invited to voluntarily participate in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient undergoing hemodialysis treatment at Vrinnevi Hospital, Norrköping Sweden
  • Provision of written
  • Ability to understand instructions and to participate in the investigations

Exclusion criteria

Exclusion Criteria:

  • Ongoing acute illness
  • Hospitalization within 4 weeks prior to enrollment
  • Unability to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
25 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Intra-dialytic systolic blood pressure fall of 20 mmHg or larger

    Difference between pre-dialytic and intra-dialytic systolic blood pressure

    Time frame: Up to 1 week

  2. Post-dialytic orthostatic systolic blood pressure fall of 20 mmHg or larger

    Change between supine and upright systolic blood pressure

    Time frame: Up to 1 week

07

Study locations

1 site
  • Vrinnevi Hospital
    Norrköping, Östergötland, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Aug 2024, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2024
First posted
Apr 4, 2024
StartActual
Apr 8, 2024
Primary completionActual
Aug 30, 2024
CompletionActual
Aug 30, 2024
Last update
Nov 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06348589
Lead sponsor
Vrinnevi Hospital
Responsible party
Magnus Wijkman (Principal Investigator, Medically Responsible Physician at the Section for Endocrinology and Diabetology, Vrinnevi Hospital) — Principal investigator
First posted
Apr 4, 2024
Start date
Apr 8, 2024
Primary completion
Aug 30, 2024
Completion
Aug 30, 2024
Last update
Nov 14, 2024

Study contacts

Magnus O Wijkman, MD, PhD
principal investigator · Vrinnevi Hospital, Department of Internal Medicine, Section of Endocrinology and Diabetology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion